IL13 and Alzheimer disease: Alongside dupilumab, tralokinumab, an anti-IL-13 inhibitor, has shown sustained efficacy and acceptable safety over up to four years in adults with moderate-to-severe AD, contributing to the expanding arsenal of targeted biologic therapies [31].